Compositions and methods for the treatment of immune related diseases
The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
1. An anti-TIGIT antibody, or antigen-binding fragment thereof, comprising a light chain comprising an HVR-L1 comprising SEQ ID NO: 23, an HVR-L2 comprising SEQ ID NO: 24, and an HVR-L3 comprising SEQ ID NO: 25, and a heavy chain comprising an HVR-H1 comprising SEQ ID NO: 26, an HVR-H2 comprising SEQ ID NO: 27, and an HVR-H3 comprising SEQ ID NO: 28.
2. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody light chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 21.
3. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 2 , wherein the antibody heavy chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22.
4. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody heavy chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 22.
5. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody is a humanized antibody, a chimeric antibody, a bispecific antibody, a heteroconjugate antibody, or an immunotoxin.
6. An anti-TIGIT antibody, or antigen-binding fragment thereof, comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 22.
7. An anti-TIGIT antibody, or antigen-binding fragment thereof, comprising a light chain comprising an HVR-L1 comprising SEQ ID NO: 31, an HVR-L2 comprising SEQ ID NO: 32, and an HVR-L3 comprising SEQ ID NO: 33, and a heavy chain comprising an HVR-H1 comprising SEQ ID NO: 34, an HVR-H2 comprising SEQ ID NO: 35, and an HVR-H3 comprising SEQ ID NO: 36.
8. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 7 , wherein the antibody light chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 29.
9. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 8 , wherein the antibody heavy chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 30.
10. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 7 , wherein the antibody heavy chain comprises an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 30.
11. The anti-TIGIT antibody, or antigen-binding fragment thereof, of claim 7 , wherein the antibody is a humanized antibody, a chimeric antibody, a bispecific antibody, a heteroconjugate antibody, or an immunotoxin.
12. An anti-TIGIT antibody, or antigen-binding fragment thereof, comprising a light chain comprising the amino acid sequence set forth in SEQ ID NO: 29 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30.